RHYTHM PHARMACEUTICALS, INC. Operating Expenses
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Operating Expenses of $136.57 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2021-03-01
- RHYTHM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2020-12-31 was $35.07M, a 2.48% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2020-09-30 was $34.28M, a 7.61% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2020-06-30 was $31.92M, a 27.70% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. operating expenses for the quarter ending 2020-03-31 was $35.30M, a 15.66% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. operating expenses for fiscal 2020 was $136.57M, a 6.46% decline from fiscal 2019.
- RHYTHM PHARMACEUTICALS, INC. operating expenses for fiscal 2019 was $146.00M, a 86.18% increase from fiscal 2018.
- RHYTHM PHARMACEUTICALS, INC. operating expenses for fiscal 2018 was $78.42M, a 141.94% increase from fiscal 2017.
- RHYTHM PHARMACEUTICALS, INC. operating expenses for fiscal 2017 was $32.41M, a 25.12% increase from fiscal 2016.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-12-31 | $35.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $69.36M derived: sum of 2 quarters · filed 2021-03-01 | $101.28M derived: sum of 3 quarters · filed 2021-03-01 | $136.57M 10-K · filed 2021-03-01 |
| 2020-09-30 | $34.28M 10-Q · filed 2020-11-02 | $66.20M derived: sum of 2 quarters · filed 2020-11-02 | $101.50M 10-Q · filed 2020-11-02 | $135.73M derived: sum of 4 quarters · filed 2020-11-02 |
| 2020-06-30 | $31.92M 10-Q · filed 2020-08-03 | $67.22M 10-Q · filed 2020-08-03 | $101.44M derived: sum of 3 quarters · filed 2020-08-03 | $138.55M derived: sum of 4 quarters · filed 2020-11-02 |
| 2020-03-31 | $35.30M 10-Q · filed 2020-05-04 | $69.52M derived: sum of 2 quarters · filed 2020-05-04 | $106.63M derived: sum of 3 quarters · filed 2020-11-02 | $150.78M derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-12-31 | $34.22M 10-K · filed 2020-03-02 | $71.33M derived: sum of 2 quarters · filed 2020-11-02 | $115.48M derived: sum of 3 quarters · filed 2020-11-02 | $146.00M 10-K · filed 2021-03-01 |
| 2019-09-30 | $37.11M 10-Q · filed 2020-11-02 | $81.26M derived: sum of 2 quarters · filed 2020-11-02 | $111.78M 10-Q · filed 2020-11-02 | $138.93M derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-06-30 | $44.15M 10-Q · filed 2020-08-03 | $74.67M 10-Q · filed 2020-08-03 | $101.82M derived: sum of 3 quarters · filed 2020-08-03 | $121.06M derived: sum of 4 quarters · filed 2020-08-03 |
| 2019-03-31 | $30.52M 10-Q · filed 2020-05-04 | $57.67M derived: sum of 2 quarters · filed 2020-05-04 | $76.92M derived: sum of 3 quarters · filed 2020-05-04 | $91.94M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | $27.15M 10-K · filed 2020-03-02 | $46.40M derived: sum of 2 quarters · filed 2020-03-02 | $61.42M derived: sum of 3 quarters · filed 2020-03-02 | $78.42M 10-K · filed 2021-03-01 |
| 2018-09-30 | $19.24M 10-K · filed 2020-03-02 | $34.27M derived: sum of 2 quarters · filed 2020-03-02 | $51.27M 10-Q · filed 2019-11-01 | $62.25M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $15.02M 10-K · filed 2020-03-02 | $32.02M 10-Q · filed 2019-07-29 | $43.01M derived: sum of 3 quarters · filed 2020-03-02 | $51.29M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $17.00M 10-K · filed 2020-03-02 | $27.98M derived: sum of 2 quarters · filed 2020-03-02 | $36.27M derived: sum of 3 quarters · filed 2020-03-02 | $43.02M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $10.98M 10-K · filed 2019-03-08 | $19.27M derived: sum of 2 quarters · filed 2019-03-08 | $26.02M derived: sum of 3 quarters · filed 2019-03-08 | $32.41M 10-K · filed 2020-03-02 |
| 2017-09-30 | $8.29M 10-K · filed 2019-03-08 | $15.04M derived: sum of 2 quarters · filed 2019-03-08 | $21.43M 10-Q · filed 2018-11-09 | $29.80M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-06-30 | $6.75M 10-K · filed 2019-03-08 | $13.14M 10-Q · filed 2018-08-08 | $21.52M derived: sum of 3 quarters · filed 2019-03-08 | $27.92M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-03-31 | $6.39M 10-K · filed 2019-03-08 | $14.76M derived: sum of 2 quarters · filed 2019-03-08 | $21.16M derived: sum of 3 quarters · filed 2019-03-08 | $26.90M derived: sum of 4 quarters · filed 2019-03-08 |
| 2016-12-31 | $8.38M 8-K · filed 2018-11-09 | $14.78M derived: sum of 2 quarters · filed 2018-11-09 | $20.51M derived: sum of 3 quarters · filed 2018-11-09 | $25.91M 10-K · filed 2019-03-08 |
| 2016-09-30 | $6.40M 8-K · filed 2018-11-09 | $12.14M derived: sum of 2 quarters · filed 2018-11-09 | $17.53M 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $5.74M 8-K · filed 2018-11-09 | $11.13M derived: sum of 2 quarters · filed 2018-11-09 | ||
| 2016-03-31 | $5.39M 8-K · filed 2018-11-09 | |||
| 2015-12-31 | $10.57M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |